Tre­vi gets $50M and David Meek­er as its new chair­man; Spark in line for a PRV

→ Tre­vi Ther­a­peu­tics in New Haven, CT has raised a $50.5 mil­lion C round. The biotech has been push­ing a drug called Nal­buphine ER through mid-stage tri­als, gath­er­ing da­ta on its abil­i­ty to re­duce itch­ing caused by a range of con­di­tions. And for­mer Sanofi-Gen­zyme chief David Meek­er is tak­ing the chair­man’s post as part of the fi­nanc­ing. New En­ter­prise As­so­ciates led the fi­nanc­ing round, which in­clud­ed new in­vestors Lund­beck­fonden Ven­tures, Omega Funds and Aper­ture Ven­ture Part­ners, along with TPG Biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER